By Fineline Cube 
Peking University Third Hospital has officially introduced palopegteriparatide, the world’s first and only approved parathyroid hormone (PTH) replacement therapy for chronic hypoparathyroidism in adults, enabled by innovative mechanisms of the Beijing Rare Disease Medicine Guarantee Pilot Zone. The once-daily subcutaneous therapy represents a breakthrough for patients with this rare endocrine disorder.
Regulatory & Access Framework
| Item | Detail |
|---|---|
| Hospital | Peking University Third Hospital |
| Therapy | Palopegteriparatide (sustained-release PTH (1-34) prodrug) |
| Indication | Chronic hypoparathyroidism in adults |
| Dosing | Once-daily subcutaneous injection |
| Access Mechanism | Beijing Rare Disease Medicine Guarantee Pilot Zone |
| China Developer | Visen Pharmaceuticals (Ascendis Pharma JV) |
| Previous Approval | Boao, Hainan (2025) |
| Global Status | World’s first approved PTH replacement therapy |
Therapeutic Innovation & Clinical Impact
- Mechanism of Action: Palopegteriparatide is a sustained-release PTH (1-34) prodrug that maintains stable physiological parathyroid hormone levels throughout the 24-hour period, addressing the fundamental hormone deficiency in chronic hypoparathyroidism.
- Treatment Paradigm Shift: Unlike conventional therapy relying on high-dose calcium and active vitamin D supplements—which can cause long-term complications like kidney stones and renal impairment—palopegteriparatide provides physiological hormone replacement, normalizing calcium metabolism while reducing complication risks.
- Patient Outcomes: Clinical studies demonstrate improved quality of life, reduced symptom burden, and better long-term safety profile compared to standard care approaches.
Chronic hypoparathyroidism affects approximately 70,000-100,000 patients in China, with many experiencing inadequate disease control and significant treatment-related complications under current management strategies.
Development & Commercial Structure
Visen Pharmaceuticals: Established in 2018 as a joint venture between Ascendis Pharma and Chinese investors, Visen holds development and commercialization rights for palopegteriparatide in China, leveraging Ascendis’s proprietary TransCon technology platform for sustained-release therapeutics.
Pilot Zone Innovation: The Beijing Rare Disease Medicine Guarantee Pilot Zone provides accelerated access pathways for breakthrough therapies addressing unmet needs in rare diseases, enabling hospitals to introduce innovative treatments ahead of full national reimbursement approval.
Hainan Precedent: Palopegteriparatide received clinical use approval in Boao, Hainan in 2025 under China’s established medical tourism and early access framework, establishing safety and efficacy data for broader mainland introduction.
Market Implications & Policy Significance
- Rare Disease Policy Leadership: Beijing’s pilot zone demonstrates China’s commitment to improving access to innovative therapies for rare disease patients, potentially serving as a model for other provinces and therapeutic areas.
- Commercial Trajectory: Initial hospital-based introduction through the pilot zone may pave the way for eventual national reimbursement inclusion and broader market access across China’s tier-1 and tier-2 hospitals.
- Competitive Landscape: As the only approved PTH replacement therapy globally, palopegteriparatide faces no direct competition, though generic calcium and vitamin D combinations remain entrenched in current treatment protocols.
Forward‑Looking Statements
This brief contains information regarding regulatory access, clinical introduction, and policy frameworks. Actual market adoption may depend on reimbursement decisions, physician education, patient awareness, and competitive dynamics.-Fineline Info & Tech